Risa

Risa Therapeutics is a biotechnology company focused on developing a novel class of small molecule therapeutics that target RNA-binding proteins (RBPs). By leveraging its proprietary platform, the company aims to address high-value targets in oncology that have historically been considered undruggable. Risa's approach involves modulating the interaction between RBPs and their RNA substrates to disrupt disease-driving pathways. The company is currently in the pre-clinical stage, advancing a pipeline of candidates designed to treat various forms of cancer. Risa is positioned at the intersection of RNA biology and small molecule drug discovery to provide innovative solutions for patients with limited treatment options.